Pancreatic Cancer Trial Enrollment Halt Damages Halozyme
Halozyme Therapeutics shares are getting pounded on Friday on news of a temporary halt of its Phase II trial enrollment and dosing for its pancreatic cancer study.
Advertisement
Recommended Stories
The Headache at the End of the Costco Gold Rush
Costco made buying a gold bar as simple as tossing it in a shopping cart. Adam Xi, 33 years old, called five different dealers to get a price he could accept for the gold bar he bought at Costco in October. Costco shoppers are spending as much as $200 million monthly on gold, according to a Wells Fargo estimate.
The Wall Street Journal•Why Nvidia Stock Plunged 10% Today
Super Micro Computer's lack of a preliminary earnings report led to a bloodbath in the sector.
Motley Fool•California loses 2 more property insurers in growing crisis
Two more property insurance companies are pulling out of California, leaving more homeowners in the state facing loss of coverage and surging premiums as insurers flee.
Fox Business•Don't buy the dip in stocks just yet as a wave of selling is about to bring the market to a bottom, according to one of the biggest bulls on Wall Street
The S&P 500 could bottom out in the next month, according to Fundstrat's head of research Tom Lee.
Business Insider•Super Micro Stock Plunges 23% On Lack Of Preliminary Results. It's A Big Sell Signal.
Super Micro stock fell hard after the data-center computer specialist didn't announce preliminary results for its fiscal Q3.
Investor's Business Daily•Why Semiconductor Stocks Were Smacked Down Today
The high-flying sector caught a bit of gloom at the end of the week due to several discouraging developments.
Motley Fool•Time to Pounce: 2 Superb Utility Stocks That Haven't Been This Cheap in at Least 10 Years
One of the fastest-growing utility stocks, along with "Wall Street's Greatest Dividend Stock," make for phenomenal buys right now.
Motley Fool•Jamie Dimon Knew Subprime 'Could Go Up In Smoke'; Now He's Worried About An Artificial Economy 'Fueled by Government Deficit Spending'
In the chaos of the 2008 recession, perhaps no bank stood more prepared than Jamie Dimon's J.P Morgan Chase & Co. (NYSE:JPM). In advance of the crisis, Jamie Dimon realized that "underwriting standards were deteriorating across the industry," with late payments on subprime loans rising. In late 2006, the bank led his firm to exit Wall Street's hot subprime business, starting with a frantic call made to J.P. Morgan's vacationing Chief of Securitized Products where he said, "I really want you to w
Benzinga•Trump Media CEO Decries Naked Short Selling; Citadel Fires Back, Stock Rises
Shares of Truth Social's parent rose in another volatile session, extending a roller-coaster stretch of trading for Donald Trump's social-media startup. On Thursday, Trump Media Chief Executive Devin Nunes sent a letter to Nasdaq CEO Adena Friedman asking her to help prevent illegal naked short selling and to make sure trading firms disclose their short positions.
The Wall Street Journal•Apple Stock Is Falling. The CEO and Other Executives Just Sold Shares.
A variety of negative factors, including concern that the company is falling behind in AI, have hurt the stock.
Barrons.com•